July 2017 | ITCC-P4 official launch

 

XenTech is proud to be part of the ITCC-P4, a new platform to accelerate drug development for children and adolescents dying of cancer.

It has been several years since XenTech developed pediatric PDX especially liver cancer PDX. Children and adolescents cancers need to be studied since the preclinical research aside from adult cancers. At XenTech, we strongly believe that strong partnerships with other specialists in the field is the key of a successfull child cancer research.

If you want to learn more about ITCC-P4, read the Press Release